The past, present, and future in antinuclear antibodies (ANA)

Autoantibodies are a hallmark of autoimmunity and, specifically, antinuclear antibodies (ANAs) are the most relevant autoantibodies present in systemic autoimmune rheumatic diseases (SARDs). Over the years, different methods from LE cell to HEp-2 indirect immunofluorescence (IIF), solid-phase assays...

Descripción completa

Detalles Bibliográficos
Autores: Irure Ventura, Juan, López Hoyos, Marcos
Tipo de recurso: artículo
Fecha de publicación:2022
País:España
Institución:Universidad de Cantabria (UC)
Repositorio:UCrea Repositorio Abierto de la Universidad de Cantabria
Idioma:inglés
OAI Identifier:oai:repositorio.unican.es:10902/28679
Acceso en línea:https://hdl.handle.net/10902/28679
Access Level:acceso abierto
Palabra clave:Antinuclear antibodies (ANAs)
Systemic autoimmune rheumatic diseases (SARDs)
Indirect immunofluorescence (IIF)
Solid-phase assays
Particle-based multi-analyte technology (PMAT)
Machine learning
id ES_b299a5ed5a31cfebbd2f7dfcabce726b
oai_identifier_str oai:repositorio.unican.es:10902/28679
network_acronym_str ES
network_name_str España
repository_id_str
spelling The past, present, and future in antinuclear antibodies (ANA)Irure Ventura, JuanLópez Hoyos, MarcosAntinuclear antibodies (ANAs)Systemic autoimmune rheumatic diseases (SARDs)Indirect immunofluorescence (IIF)Solid-phase assaysParticle-based multi-analyte technology (PMAT)Machine learningAutoantibodies are a hallmark of autoimmunity and, specifically, antinuclear antibodies (ANAs) are the most relevant autoantibodies present in systemic autoimmune rheumatic diseases (SARDs). Over the years, different methods from LE cell to HEp-2 indirect immunofluorescence (IIF), solid-phase assays (SPAs), and finally multianalyte technologies have been developed to study ANA-associated SARDs. All of them provide complementary information that is important to provide the most clinically valuable information. The identification of new biomarkers together with multianalyte platforms will help close the so-called "seronegative ga" and to correctly classify and diagnose patients with SARDs. Finally, artificial intelligence and machine learning is an area still to be exploited but in a next future will help to extract patterns within patient data, and exploit these patterns to predict patient outcomes for improved clinical management.Universidad de Cantabria20222022-01-01journal articlehttp://purl.org/coar/resource_type/c_6501NAhttp://purl.org/coar/version/c_be7fb7dd8ff6fe43info:eu-repo/semantics/articlehttps://hdl.handle.net/10902/28679Diagnostics 2022, 12, 647reponame:UCrea Repositorio Abierto de la Universidad de Cantabriainstname:Universidad de Cantabria (UC)Inglésengopen accesshttp://purl.org/coar/access_right/c_abf2Attribution 4.0 Internationalhttp://creativecommons.org/licenses/by/4.0/info:eu-repo/semantics/openAccessoai:repositorio.unican.es:10902/286792026-06-02T12:39:31Z
dc.title.none.fl_str_mv The past, present, and future in antinuclear antibodies (ANA)
title The past, present, and future in antinuclear antibodies (ANA)
spellingShingle The past, present, and future in antinuclear antibodies (ANA)
Irure Ventura, Juan
Antinuclear antibodies (ANAs)
Systemic autoimmune rheumatic diseases (SARDs)
Indirect immunofluorescence (IIF)
Solid-phase assays
Particle-based multi-analyte technology (PMAT)
Machine learning
title_short The past, present, and future in antinuclear antibodies (ANA)
title_full The past, present, and future in antinuclear antibodies (ANA)
title_fullStr The past, present, and future in antinuclear antibodies (ANA)
title_full_unstemmed The past, present, and future in antinuclear antibodies (ANA)
title_sort The past, present, and future in antinuclear antibodies (ANA)
dc.creator.none.fl_str_mv Irure Ventura, Juan
López Hoyos, Marcos
author Irure Ventura, Juan
author_facet Irure Ventura, Juan
López Hoyos, Marcos
author_role author
author2 López Hoyos, Marcos
author2_role author
dc.contributor.none.fl_str_mv Universidad de Cantabria
dc.subject.none.fl_str_mv Antinuclear antibodies (ANAs)
Systemic autoimmune rheumatic diseases (SARDs)
Indirect immunofluorescence (IIF)
Solid-phase assays
Particle-based multi-analyte technology (PMAT)
Machine learning
topic Antinuclear antibodies (ANAs)
Systemic autoimmune rheumatic diseases (SARDs)
Indirect immunofluorescence (IIF)
Solid-phase assays
Particle-based multi-analyte technology (PMAT)
Machine learning
description Autoantibodies are a hallmark of autoimmunity and, specifically, antinuclear antibodies (ANAs) are the most relevant autoantibodies present in systemic autoimmune rheumatic diseases (SARDs). Over the years, different methods from LE cell to HEp-2 indirect immunofluorescence (IIF), solid-phase assays (SPAs), and finally multianalyte technologies have been developed to study ANA-associated SARDs. All of them provide complementary information that is important to provide the most clinically valuable information. The identification of new biomarkers together with multianalyte platforms will help close the so-called "seronegative ga" and to correctly classify and diagnose patients with SARDs. Finally, artificial intelligence and machine learning is an area still to be exploited but in a next future will help to extract patterns within patient data, and exploit these patterns to predict patient outcomes for improved clinical management.
publishDate 2022
dc.date.none.fl_str_mv 2022
2022-01-01
dc.type.none.fl_str_mv journal article
http://purl.org/coar/resource_type/c_6501
NA
http://purl.org/coar/version/c_be7fb7dd8ff6fe43
dc.type.openaire.fl_str_mv info:eu-repo/semantics/article
format article
dc.identifier.none.fl_str_mv https://hdl.handle.net/10902/28679
url https://hdl.handle.net/10902/28679
dc.language.none.fl_str_mv Inglés
eng
language_invalid_str_mv Inglés
language eng
dc.rights.none.fl_str_mv open access
http://purl.org/coar/access_right/c_abf2
Attribution 4.0 International
http://creativecommons.org/licenses/by/4.0/
dc.rights.openaire.fl_str_mv info:eu-repo/semantics/openAccess
rights_invalid_str_mv open access
http://purl.org/coar/access_right/c_abf2
Attribution 4.0 International
http://creativecommons.org/licenses/by/4.0/
eu_rights_str_mv openAccess
dc.source.none.fl_str_mv Diagnostics 2022, 12, 647
reponame:UCrea Repositorio Abierto de la Universidad de Cantabria
instname:Universidad de Cantabria (UC)
instname_str Universidad de Cantabria (UC)
reponame_str UCrea Repositorio Abierto de la Universidad de Cantabria
collection UCrea Repositorio Abierto de la Universidad de Cantabria
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1869417068346998784
score 15,300724

Similares en LA Referencia